Celularity (CELU) Non-Current Debt (2023 - 2025)

Celularity (CELU) posted quarterly Non-Current Debt of $36.5 million for Q2 2025, little changed quarter-over-quarter from $36.5 million in Q1 2025.

Celularity (CELU) Non-Current Debt (2023 - 2025) Analysis & Trends

Celularity (CELU) has reported Non-Current Debt for 3 consecutive years, with $36.5 million the latest figure, recorded in Q2 2025.

In Q2 2025, Non-Current Debt changed N/A year-over-year to $36.5 million; the TTM figure through Jun 2025 stood at $36.5 million (changed N/A YoY), while the FY2024 annual figure was $35.9 million, changed N/A from the prior year.
Non-Current Debt steadied at $36.5 million in Q2 2025 per CELU's latest filing, from $36.5 million in the prior quarter.
Across five years, Non-Current Debt topped out at $36.5 million in Q1 2025 and bottomed at $4.7 million in Q1 2023.
Historically, Non-Current Debt has averaged $26.1 million across 3 years, with a median of $35.9 million in 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	138.54 Bn	130.69 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.89 Bn	77.89 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.84 Bn	59.65 Bn	1.37 Bn	-
4	Moderna	56.53 Bn	51.39 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.97 Bn	36.87 Bn	1.53 Bn	882.16 Mn
6	Alnylam Pharmaceuticals	31.53 Bn	28.22 Bn	992.69 Mn	-
7	BioNTech SE	27.70 Bn	9.31 Bn	668.28 Mn	360.97 Mn
8	Insmed	27.45 Bn	26.29 Bn	358.27 Mn	546.77 Mn
9	Royalty Pharma	27.33 Bn	26.49 Bn	-	8.96 Bn
10	Celularity	19.68 Mn	13.50 Mn	-3.27 Mn	-

Download Data